Lung Cancer, NSCLC
Conditions
Keywords
IDO enzyme, Vaccination trial, Immunotherapy, NSCLC, stage III_IV, Indeolamine 2,3 dioxygenase = IDO
Brief summary
Title: IDO peptid vaccination in combination with immune stimulating agent Aldara and the adjuvant Montanide, for treatment of patients with locally advanced or metastatic non small-cell lung cancer. A first-in-man phase I trial. Hypothesis: In this trial the investigators assess a new immunotherapeutic strategy targeting the immune inhibiting enzyme, IDO to investigate the potential of vaccination against IDO as a possible anticancer target.
Detailed description
Background: Non small-cell lung cancer (NSCLC) is a common disease with a poor prognosis when locally advanced or metastasized, despite advances in surgery, chemo- and radiation therapy. In this trial the investigators assess a new immunotherapeutic strategy targeting the immune inhibiting enzyme, IDO to investigate the potential of vaccination against IDO as a possible anticancer target. IDO has recently been recognized as an important factor in immune regulation and development of immune tolerance in the microenvironment of cancer cells. Cells that represent IDO at their surface are known to inhibit the immune system. IDO expression is seen both in cancer cells and antigen presenting cells. The vaccination against IDO expressing cells is therefore two-sided. The vaccination therapy is thought to block the development of immune tolerance induced by IDO expressing cells. At the same time the investigators aim to stimulate the production of IDO specific T-cells, hence facilitating the elimination of IDO positive tumour cells. The primary end points are safety and toxicity evaluation. Secondary end points are immunological and clinical response.
Interventions
BIOLOGICALIDO peptide vaccination
Vaccination every second week
Sponsors
Inge Marie Svane
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1\. Histological or cytological verified non small cell lung cancer 2. Metastatic or locally advanced incurable stage III-IV NSCLC 3. Patients need to be off chemotherapy treatment 4. Evaluable disease according to RECIST V. 1,1 criteria 5. Patients must be HLA-A2 positive 6. Patients \> 18 years old 7. Performance status 0-1 8. Life expectancy of \> 3 months 9. Acceptable bone marrow function, defined as a. White blood cell count \> 2,5 \* 109 /l b. Neutrophil count\> 1,5 \* 109 /l c. Platelet count \> 75 \* 109/l 10. Creatinin measured \< 2,5 \* upper limit value 11. Acceptable liver function, defined as 1. ASAT \< 100 U/L 2. Bilirubin \< 30 U/L 12. Women with child-bearing potential must have controlled s-hcg before inclusion 13. Patients must provide written informed concent before inclusion 13. Termination of chemotherapy treatment \> 28 days before inclusion 14\. Termination of radiotherapy treatment \> 28 days before inclusion 15\. Inclusion at least \> 4 weeks after complicated gastric surgery \-
Exclusion criteria
1. Other malignancies except from non-melanoma skin cancer in the previous 5 years until study inclusion 2. Brain metastasis are allowed after radical excision, and if the patient at least 1 month afterwards is not in clinical or radiographic progression 3. Patients with active gastric ulcer disease; patients taking antacid treatment can be included. 4. Severe medical condition, severe asthma, severe COLD, severe arteriosclerosis or diabetic disease 5. Acute or chronic infection (ie. HIV, hepatitis, tuberculosis) 6. Severe allergic reaction or previous anaphylactic shock 7. Autoimmune diseases (ie. autoimmune neutropenia/thrombopenia, hæmolytic anaemia, systemic lupus erythematosis, Sjøgrens disease, sclerodermia, Goodpastures syndrome, Addisons disease, active Graves disease) 8. Pregnant or lactating women 9. Psychiatric disease, which can influence compliance 10. Known hypersensitivity towards the adjuvance Montanide, the Aldara creme, or adhesive tape. 11. Treatment with immunosuppressive therapy (ie. dexamethasone, methotrexate) 12. Treatment with other experimental therapy 13. Treatment with other anti-cancer therapy, except from treatment of osteoporosis 14. No systemic chemotherapy, immunotherapy or radiation therapy (except locally) are allowed until 28 days before inclusion. \-
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| evidence of toxicity | 12 months | CTCAE = Common Terminology Criteria for Adverse Events v. 3.0 will be used for registration of toxicity |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| evaluation of immunological and clinical responses | 18 months | immunological assays will be used to identify immunological responses. CT scans will be used for evaluation of clinical responses. |
Countries
Denmark
Outcome results
None listed